Provided is a compound having the structure:
(SIG)-(SI-MOD).sub.m
where SIG is a signaling molecule, SI is a self-immolative structure bound to SIG such that SIG has a reduced signal relative to the signal of SIG without SI, MOD is a moiety bound to SI that is subject to modification by an activator, and m is an integer from 1 to about 10. When MOD is modified by an activator, SI is destabilized and self-cleaved from SIG such that SIG generates an increased signal. Also provided are methods of determining whether a sample, such as a cell, comprises an activator, such as a nitroreducase, using the compound. Further provided are methods of determining whether a mammalian cell is hypoxic using the compound where nitroreductase is the activator. A method of detecting a microorganism that comprises a nitroreductase using the compound where nitroreductase is the activator is also provided.

Provided herein are compounds of the formulas: (I) wherein: n, X.sub.2, R.sub.3, R.sub.3, R.sub.4, R.sub.4, R.sub.5, R.sub.5, R.sub.6, and R.sub.6 are as defined herein. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds may be used for the treatment of diseases, including diabetic peripheral neuropathy or cancer. ##STR00001##

Provided herein are compounds of the formulas: (I) wherein: n, X.sub.2, R.sub.3, R.sub.3, R.sub.4, R.sub.4, R.sub.5, R.sub.5, R.sub.6, and R.sub.6 are as defined herein. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds may be used for the treatment of diseases, including diabetic peripheral neuropathy or cancer. ##STR00001##

The present invention is directed to a compound represented by Structural Formula (A):

##STR00001##

or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.

The present invention is directed to a compound represented by Structural Formula (A):

##STR00001##

or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.

The present invention relates to novel coumarin glyoxylates, a process for their preparation and their use as photoinitiators in photopolymerization compositions. The invention also concerns a process for the photopolymerization of compositions comprising said coumarin glyoxylates.

The present invention relates to novel coumarin glyoxylates, a process for their preparation and their use as photoinitiators in photopolymerization compositions. The invention also concerns a process for the photopolymerization of compositions comprising said coumarin glyoxylates.

The present invention relates to novel coumarin glyoxylates, a process for their preparation and their use as photoinitiators in photopolymerization compositions. The invention also concerns a process for the photopolymerization of compositions comprising said coumarin glyoxylates.

The present invention relates to novel coumarin glyoxylates, a process for their preparation and their use as photoinitiators in photopolymerization compositions. The invention also concerns a process for the photopolymerization of compositions comprising said coumarin glyoxylates.

Compounds of formula I:

##STR00001##

are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.